Paper Details

  1. Home
  2. Paper Details

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Author: CalvoKatherine R, FarooquiMohammed Z H, HermanSarah E M, LeeYuh Shan, MaricIrina, MartiGerald E, MartyrSabrina, NiemannCarsten U, SalemDalia, SkarzynskiMartin, SotoSusan, Stetler-StevensonMaryalice, ValdezJanet, WiestnerAdrian, YuanConstance

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ibrutinib, a Bruton's tyrosine kinase inhibitor, has shown promising results in clinical trials when combined with anti-CD20 monoclonal antibodies for chronic lymphocytic leukemia. This study investigates in vivo ibrutinib treatment effects that could explain the paradox of decreased CD20 expression and inhibition of cellular effector mechanisms observed in preclinical studies.
Paper Details　
Original Abstract of the Article :
Clinical trials of ibrutinib combined with anti-CD20 monoclonal antibodies (mAb) for chronic lymphocytic leukemia (CLL) report encouraging results. Paradoxically, in preclinical studies, in vitro ibrutinib was reported to decrease CD20 expression and inhibit cellular effector mechanisms. We therefor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26283682

データ提供：米国国立医学図書館（NLM）

Ibrutinib and Anti-CD20 Antibodies: Navigating the Complexities of Combination Therapy

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that requires effective treatment to manage the disease and improve patient outcomes. This study investigates the potential interactions between ibrutinib, a Bruton's tyrosine kinase inhibitor, and anti-CD20 monoclonal antibodies (mAb) in the treatment of CLL. The authors explore the complex interplay of these two therapies, examining their effects on CD20 expression and cellular effector mechanisms.

A Complex Dance of Therapies: Ibrutinib and Anti-CD20 Antibodies in CLL

This study delves into the complex interactions between ibrutinib and anti-CD20 antibodies in the treatment of CLL. The authors highlight the paradoxical effects of ibrutinib on CD20 expression and cellular effector mechanisms, raising important questions about the optimal use of these therapies in combination. This research is essential for understanding the complex interplay of these two therapies and maximizing their effectiveness for patients with CLL.

Navigating the Desert of Cancer Treatment: Finding the Right Combination for CLL

This research provides crucial insights into the complex interactions between ibrutinib and anti-CD20 antibodies in the treatment of CLL. The authors' findings highlight the need for careful consideration of these interactions when developing combination therapies for this type of blood cancer. This research is a vital step towards optimizing treatment strategies for CLL and improving outcomes for patients with this challenging disease.

Dr. Camel's Conclusion

Cancer treatment often involves a complex interplay of different therapies, like navigating a shifting landscape of dunes. This research delves into the intricate interactions between ibrutinib and anti-CD20 antibodies in the treatment of CLL, highlighting the importance of understanding these complexities for optimizing treatment strategies and improving patient outcomes. It’s a reminder that finding the right combination of therapies is crucial for navigating the desert of cancer treatment and ensuring the best possible results for patients.

Date :
  1. Date Completed 2016-10-13
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

26283682

DOI: Digital Object Identifier

NIHMS716586

Related Literature

Article Analysis
・Effects of ibrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.